Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When people research regenerative medicine, they often come across two phrases that sound similar but describe quite different approaches: treatments that use a patient’s own cells, and treatments that use cells from another person. Understanding this difference can help you ask better questions before any consultation. This article explains the idea in plain language for readers in Japan and overseas who are exploring adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic.
The short answer
“Autologous” simply means that the cells come from the same person who later receives them. “Donor” cells, often called allogeneic cells, come from a different individual. In the adipose-derived approach described by Grand Green Osaka Umekita Clinic, mesenchymal stem cells are taken from your own fat tissue, cultured and expanded at a specialized facility, and then returned to you by IV infusion. Because the cells are your own, the risk of rejection or allergic reaction is considered lower than with donor cells or artificial materials. Lower does not mean absent, and no regenerative treatment can be promised to work for everyone. Whether it is suitable for you is something only a physician can judge after an examination.
Why the source of the cells matters
Your immune system is designed to recognize what belongs to your body and what does not. When cells from another person are introduced, the immune system may treat them as foreign. This is the basic reason that organ transplants require careful matching and often long-term medication to suppress immune responses. Cell therapies that use donor material may face a similar question, even though the amounts and the methods of administration are very different from an organ transplant.
Using your own cells avoids the question of matching between two people. It also means the starting material is limited to what your own body can provide, and the quality of that material can vary from person to person. Age, general health, and other factors may influence how cells behave during culture. For that reason, the doctor’s explanation of what to expect, and what cannot be predicted, is an important part of the decision.
How the autologous process works
The process starts with a small amount of fat tissue. It is collected under local anesthesia through a small incision, and only a few rice-grain-sized pieces are needed. The tissue is sent to a specialized culture facility, where the mesenchymal stem cells it contains are isolated and expanded. Once enough cells have been prepared, they are returned to you by IV drip. Both the collection and the infusion are done on an outpatient basis, so hospitalization is not required.
Mesenchymal stem cells are somatic stem cells found in fat tissue, bone marrow, and other places. They can differentiate into fat, bone, and cartilage cells, and they have been reported to secrete anti-inflammatory substances and growth factors that support the repair of damaged tissue. Fat tissue is considered to contain more of these cells than bone marrow, and collecting it is generally a smaller burden on the body. These are descriptions of research findings and general tendencies, not guarantees of an individual result.
What using your own cells does not change
It is easy to hear “your own cells” and assume the treatment carries no concerns at all. That would be a misunderstanding. Several points still apply regardless of where the cells come from.
- Fat collection is a minor procedure, and any procedure can involve discomfort, bleeding, bruising, or infection at the collection site.
- IV infusion can also involve risks, and your doctor should explain possible side effects and how they would be handled.
- Evidence for regenerative treatments is still developing, and results from one study cannot be assumed to apply to every person or condition.
- Quality control during cell culture matters, which is one reason Japanese law places requirements on facilities and treatment plans.
If you currently receive standard medical care, this therapy should not be viewed as a replacement for it. It is better discussed with your treating doctors as one possible option alongside your existing care.
How Japan regulates cell treatments
In Japan, regenerative medicine provided by clinics is overseen under the Act on the Safety of Regenerative Medicine. Under this framework, a provider submits a treatment plan that is reviewed by a certified committee, and the plan is then filed with the authorities. Cell culture and processing are expected to take place at facilities that meet the required standards. This system is intended to support safety management, but it does not guarantee that a treatment will be effective.
It is also important to know that adipose-derived stem cell therapy is a self-pay treatment, meaning it is not covered by public health insurance. Fees, the number of treatments, the treatment schedule, and the risks should all be confirmed with a doctor before you decide anything.
Questions to bring to your consultation in Osaka
Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, and offers information pages for international patients in multiple languages. A consultation is the place to discuss your own medical history and whether this type of treatment is appropriate. It can help to prepare questions in advance.
- Is my health condition suitable for a treatment that uses my own cells, and are there reasons it might not be advisable?
- What are the possible risks and side effects of both fat collection and infusion?
- How long does culture take, and how many visits are involved?
- What are the total fees, and what is and is not included?
- How would this fit with the medications and treatments I am already receiving?
- What happens if the cultured cells do not meet quality standards?
Bringing your medical records, a list of current medications, and your questions in writing can make the conversation more productive, particularly if you are traveling from abroad and have limited time.
Summary
Autologous stem cell therapy uses cells taken from your own body, which is why the risk of rejection is considered lower than with donor cells. That is a meaningful difference, but it does not remove the need to consider the risks of collection and infusion, the limits of current evidence, or the fact that this is a self-pay treatment provided under Japanese regulation. The most useful next step is an individual consultation with a physician, where your health history, expectations, and questions can be discussed openly. Please remember that this article is general information and not medical advice or a promise of any outcome.
- Cells from your own fatSmall collection, local anesthesia
- Cultured at a facilityExpanded before return
- Returned by IV dripOutpatient, no hospital stay
- Doctor consultation firstRisks and fees confirmed
This figure is a conceptual diagram summarizing the article
References
- PubMed: Mesenchymal stem cells for recurrent miscarriage. (2026)
- PubMed: Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells. (2013)
- PubMed: Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. (2008)
- PMC: The Importance of HLA Assessment in "Off-the-Shelf" Allogeneic Mesenchymal Stem Cells Based-Therapies. (2019)
- PMC: Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. (2014)
- PMC: Clinical implication of allogenic implantation of adipogenic differentiated adipose-derived stem cells. (2014)
- PMC: Allogeneic ADSCs Induce the Production of Alloreactive Memory-CD8 T Cells through HLA-ABC Antigens. (2020)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.